GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Capex-to-Operating-Income

KLTO (Klotho Neurosciences) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Klotho Neurosciences's Capital Expenditure for the three months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-1.59 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Klotho Neurosciences Capex-to-Operating-Income Historical Data

The historical data trend for Klotho Neurosciences's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Capex-to-Operating-Income Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
- - - -

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Klotho Neurosciences's Capex-to-Operating-Income

For the Biotechnology subindustry, Klotho Neurosciences's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klotho Neurosciences's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Capex-to-Operating-Income falls into.


;
;

Klotho Neurosciences Capex-to-Operating-Income Calculation

Klotho Neurosciences's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.123) / -5.54
=N/A

Klotho Neurosciences's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -1.587
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Klotho Neurosciences  (NAS:KLTO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Klotho Neurosciences Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Klotho Neurosciences Business Description

Traded in Other Exchanges
N/A
Address
13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.